Okamura Corporation (TYO:7994)
Japan · Delayed Price · Currency is JPY 2,401.00
+19.00 (0.80%)
Aug 1, 2025, 3:30 PM JST
Revance Therapeutics Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 314,527 | 298,295 | 277,015 | 261,175 | 244,454 | Upgrade | |
Revenue Growth (YoY) | 5.44% | 7.68% | 6.07% | 6.84% | -3.44% | Upgrade |
Cost of Revenue | 208,997 | 198,522 | 188,010 | 177,588 | 164,341 | Upgrade |
Gross Profit | 105,530 | 99,773 | 89,005 | 83,587 | 80,113 | Upgrade |
Selling, General & Admin | 79,277 | 73,387 | 69,264 | 65,431 | 63,537 | Upgrade |
Operating Expenses | 81,593 | 75,735 | 71,632 | 67,614 | 65,937 | Upgrade |
Operating Income | 23,937 | 24,038 | 17,373 | 15,973 | 14,176 | Upgrade |
Interest Expense | -303 | -153 | -180 | -151 | -163 | Upgrade |
Interest & Investment Income | 1,061 | 1,008 | 926 | 888 | 907 | Upgrade |
Earnings From Equity Investments | 1,399 | 510 | 469 | 395 | 193 | Upgrade |
Currency Exchange Gain (Loss) | 14 | 182 | 339 | 374 | - | Upgrade |
Other Non Operating Income (Expenses) | 524 | 813 | 379 | 293 | 543 | Upgrade |
EBT Excluding Unusual Items | 26,632 | 26,398 | 19,306 | 17,772 | 15,656 | Upgrade |
Gain (Loss) on Sale of Investments | 4,035 | 3,366 | 4,343 | 3,898 | 2,340 | Upgrade |
Gain (Loss) on Sale of Assets | -173 | -171 | -382 | -283 | 154 | Upgrade |
Asset Writedown | -14 | -35 | -143 | -76 | -41 | Upgrade |
Other Unusual Items | -1 | -1 | 24 | 357 | -102 | Upgrade |
Pretax Income | 30,479 | 29,557 | 23,148 | 21,668 | 18,007 | Upgrade |
Income Tax Expense | 8,398 | 8,929 | 6,935 | 6,594 | 6,057 | Upgrade |
Earnings From Continuing Operations | 22,081 | 20,628 | 16,213 | 15,074 | 11,950 | Upgrade |
Minority Interest in Earnings | -36 | -348 | -307 | -82 | 21 | Upgrade |
Net Income | 22,045 | 20,280 | 15,906 | 14,992 | 11,971 | Upgrade |
Net Income to Common | 22,045 | 20,280 | 15,906 | 14,992 | 11,971 | Upgrade |
Net Income Growth | 8.70% | 27.50% | 6.10% | 25.24% | 21.52% | Upgrade |
Shares Outstanding (Basic) | 95 | 95 | 97 | 99 | 106 | Upgrade |
Shares Outstanding (Diluted) | 95 | 95 | 97 | 99 | 106 | Upgrade |
Shares Change (YoY) | -0.01% | -2.92% | -1.64% | -6.85% | -3.39% | Upgrade |
EPS (Basic) | 232.94 | 214.27 | 163.14 | 151.25 | 112.50 | Upgrade |
EPS (Diluted) | 232.94 | 214.27 | 163.14 | 151.25 | 112.50 | Upgrade |
EPS Growth | 8.71% | 31.34% | 7.86% | 34.44% | 25.79% | Upgrade |
Free Cash Flow | -15,475 | 5,583 | 1,122 | 91 | 22,178 | Upgrade |
Free Cash Flow Per Share | -163.51 | 58.99 | 11.51 | 0.92 | 208.43 | Upgrade |
Dividend Per Share | 94.000 | 86.000 | 55.000 | 40.000 | 32.000 | Upgrade |
Dividend Growth | 9.30% | 56.36% | 37.50% | 25.00% | - | Upgrade |
Gross Margin | 33.55% | 33.45% | 32.13% | 32.00% | 32.77% | Upgrade |
Operating Margin | 7.61% | 8.06% | 6.27% | 6.12% | 5.80% | Upgrade |
Profit Margin | 7.01% | 6.80% | 5.74% | 5.74% | 4.90% | Upgrade |
Free Cash Flow Margin | -4.92% | 1.87% | 0.40% | 0.03% | 9.07% | Upgrade |
EBITDA | 30,726 | 30,570 | 23,586 | 21,710 | 20,181 | Upgrade |
EBITDA Margin | 9.77% | 10.25% | 8.51% | 8.31% | 8.25% | Upgrade |
D&A For EBITDA | 6,789 | 6,532 | 6,213 | 5,737 | 6,005 | Upgrade |
EBIT | 23,937 | 24,038 | 17,373 | 15,973 | 14,176 | Upgrade |
EBIT Margin | 7.61% | 8.06% | 6.27% | 6.12% | 5.80% | Upgrade |
Effective Tax Rate | 27.55% | 30.21% | 29.96% | 30.43% | 33.64% | Upgrade |
Updated Feb 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.